Methohexital

Today, Methohexital is a topic of great relevance and interest to a wide variety of people. Whether due to its impact on society, its influence on popular culture or its importance in the professional field, Methohexital has become a recurring topic of conversation around the world. With its variety of facets and its ability to generate debate, Methohexital remains an ever-evolving topic that continues to capture the audience's attention and curiosity. In this article, we will explore in detail different aspects of Methohexital, its impact and its relevance today.

Methohexital
Skeletal formula
Ball-and-stick model
Clinical data
Trade namesBrevital Sodium
Other namesMethohexitone
AHFS/Drugs.comConsumer Drug Information
License data
Routes of
administration
Intravenous, rectal
Drug classBarbiturate
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityI.V. ~100%
Rectal ~17%
MetabolismLiver
Elimination half-life5.6 ± 2.7 minutes
Excretionexcreted in feces
Identifiers
  • 5-Hex-3-yn-2-yl-1-methyl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.005.272 Edit this at Wikidata
Chemical and physical data
FormulaC14H18N2O3
Molar mass262.309 g·mol−1
3D model (JSmol)
  • O=C1N(C(=O)NC(=O)C1(C\C=C)C(C#CCC)C)C
  • InChI=1S/C14H18N2O3/c1-5-7-8-10(3)14(9-6-2)11(17)15-13(19)16(4)12(14)18/h6,10H,2,5,9H2,1,3-4H3,(H,15,17,19) checkY
  • Key:NZXKDOXHBHYTKP-UHFFFAOYSA-N checkY
  (verify)

Methohexital or methohexitone (marketed under the brand names Brevital and Brietal) is a drug which is a barbiturate derivative. It is classified as short-acting, and has a rapid onset of action. It is similar in its effects to sodium thiopental, a drug with which it competed in the market for anesthetics.

Pharmacology

Methohexital binds to a distinct site which is associated with Cl ionophores at GABAA receptors. This increases the length of time which the Cl ionopores are open, thus causing an inhibitory effect.

Metabolism of methohexital is primarily hepatic via demethylation and oxidation. Side-chain oxidation is the primary means of metabolism involved in the termination of the drug's biological activity.

Indications

Methohexital is primarily used to induce anesthesia, and is generally provided as a sodium salt (i.e. methohexital sodium). It is only used in hospital or similar settings, under strict supervision. It has been commonly used to induce deep sedation or general anesthesia for surgery and dental procedures. Unlike many other barbiturates, methohexital actually lowers the seizure threshold, a property that makes it particularly useful when anesthesia is provided for an electroconvulsive therapy (ECT). Its rapid recovery rate with consciousness being gained within three to seven minutes after induction and full recovery within 30 minutes is a major advantage over other ECT barbiturates.

Synthesis

Methohexital can be synthesized in the classic manner of making barbituric acid derivatives, in particular by the reaction of malonic ester derivatives with derivatives of urea. The resulting allyl-(1-methyl-2-pentynyl) malonic ester is synthesized by subsequent alkylation of the malonic ester itself, beginning with 2-bromo-3-hexyne, which gives (1-methyl-2-pentynyl)malonic ester, and then by allylbromide. In the final step, reaction of the disubstituted malonic ester with N-methylurea gives methohexital.

Methohexital synthesis

References

  1. ^ a b c "Brevital Sodium". DailyMed. July 24, 2019. Retrieved November 20, 2019.
  2. ^ "Methohexital". MeSH.
  3. ^ Katzung BG. Basic and Clinical Pharmacology (10th ed.). pp. 406–407.
  4. ^ a b Schulgasser H, Borowitz AH (August 1963). "Methohexital anaesthesia in electroconvulsive therapy". South African Medical Journal. 37: 870–1. PMID 14045806.
  5. ^ US 2872448, Doran WJ, "1,5,5-Trisubstituted barbituric acids", issued February 3, 1959, assigned to Eli Lily and Company  (U.S. patent 2,872,448)

External links